This comparison looks at two healthcare-adjacent growth companies that operate in quite different parts of the market. HIMS (Hims & Hers Health) is a consumer-oriented telehealth business expanding quickly yet dealing with regulatory questions, whereas VEEV (Veeva Systems) is a more mature enterprise software provider focused on pharmaceutical and biotech clients. The contrast matters most for investors deciding between higher-growth, higher-volatility opportunities and steadier, profitable recurring-revenue models. Growth-focused traders may lean toward HIMS and its catalysts, while those preferring stability and predictable cash flow could find VEEV more suitable.
HIMS, or Hims & Hers Health, runs a multi-specialty telehealth platform that provides prescription medications, mental-health support, dermatology, sexual-health treatments, and more recently weight-loss products. The company has expanded rapidly, reporting full-year revenue near $2.3 billion in its latest fiscal year, up roughly 59%, with subscribers exceeding 2.5 million. Growth has centered on personalized and weight-loss offerings, although the company notes that the majority of U.S. revenue now comes from non-GLP-1 products. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent trading has shown notable volatility. The removal of semaglutide from the FDA's drug shortage list introduced uncertainty around compounded GLP-1 sales, a key growth area, and led to a meaningful pullback from prior highs. The stock maintains a high beta, indicating larger price swings relative to the broader market. In recent weeks, mixed earnings—with revenue beating estimates but guidance coming in softer—along with talks with Novo Nordisk about offering branded obesity treatments have influenced sentiment. Margin pressure from infrastructure spending continues to draw attention.
VEEV, or Veeva Systems, supplies cloud software, data, and consulting solutions designed specifically for the global life sciences sector. Its offerings include the Development Cloud for clinical, regulatory, and safety applications, the Commercial Cloud with CRM and analytics, and the Data Cloud. The business generates recurring subscription revenue from pharmaceutical, biotech, and medical-device customers and has maintained consistent profitability.
Performance has been steady amid some challenges. Quarterly revenue has increased about 16% year over year, with non-GAAP earnings surpassing expectations and operating margins near 30%. Demand for system modernization, the Crossix analytics platform, and early AI features has supported growth. Sentiment has softened due to concerns over potential CRM customer transitions and a share-price decline in recent months. Management continues to highlight diversification and AI product development as central to ongoing progress. From what I see, VEEV’s subscription model provides a clearer view of future revenue streams.
The core difference lies in their business models. HIMS sells directly to consumers and remains sensitive to marketing efficiency, customer-acquisition costs, and regulatory changes in telehealth and weight-loss treatments. VEEV sells enterprise software on a subscription basis, which delivers more predictable recurring revenue and higher operating margins. This distinction largely accounts for their different risk profiles: HIMS shows elevated beta and margins compressed to low single digits, while VEEV sustains margins near 30% and a more stable earnings foundation.
Growth drivers also vary. HIMS focuses on platform expansion across new categories and addressing the GLP-1 regulatory overhang through partnerships and diversification. VEEV relies on enterprise digital transformation, data-analytics demand, and a multi-year AI roadmap. Both operate in healthcare spaces, yet HIMS targets consumer telehealth while VEEV serves B2B life-sciences technology. Market sentiment has been uneven for both recently—HIMS due to regulatory and guidance issues, VEEV due to CRM migration questions—though their volatility levels remain clearly distinct.
Considering factors such as trend consistency, margin stability, and revenue predictability, Tickeron’s AI would likely lean toward VEEV in the current setting. Veeva’s steadier growth, stronger profitability, and recurring subscription model offer a more consistent technical and fundamental profile compared with HIMS’s higher-volatility, catalyst-driven approach. At the same time, HIMS could deliver greater upside for momentum-oriented traders if regulatory clarity on GLP-1 products improves or partnership developments emerge. The AI’s assessment remains probabilistic, reflecting the trade-off between VEEV’s stability and HIMS’s higher-growth, higher-risk positioning.
In my own review process, I often turn to Tickeron’s AI Trading Bots to test how different automated strategies perform across volatile names like these. The platform’s bots cover a range of hold periods, risk levels, and stock universes, allowing me to match approaches to specific objectives without sorting through every option manually. This helps add a layer of quantitative perspective to the fundamental and technical analysis.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day moving average for VEEV crossed bearishly below the 50-day moving average on November 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VEEV as a result. In 54 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 69%.
The Moving Average Convergence Divergence Histogram (MACD) for VEEV turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 33 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 66%.
VEEV moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VEEV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
The Aroon Indicator for VEEV entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +0.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where VEEV advanced for three days, in 179 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
VEEV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. VEEV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 64 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.617) is normal, around the industry mean (4.523). VEEV has a moderately high P/E Ratio (48.989) as compared to the industry average of (12.601). Projected Growth (PEG Ratio) (1.248) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (12.739) is also within normal values, averaging (6.105).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VEEV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of industry-specific, cloud-based software solutions for the life sciences industry
Industry ServicestotheHealthIndustry